Wall Street Journal Article

ac253189

New member
It was either yesterday or thursday when i saw this article in the WSJ. It was basically talking about companies that hire other companies to make drugs in bulk. I guess there have been a lot of issues with making drugs in bulk, b/c they arnt monitored as well. Anyways, the example they gave was about a doctor who was using one of these bulk drugs, happened to be a steroid. The steroid ended up growing a fungus in the patients spinal cord. I thought this was weird and kinda scarey at the same time. Makes me want to only shoot human grade from now. what do you guys think?
 
it's a bit more complicated than it seems.

the steroid injected (probably into the epidural space) was a cortisone derivative, not an anabolic steroid. It was injected for it's anti-inflammatory properties to help with sciatica (nerve root irritation from a prolapsed lumbar disc).

Corticosteroids are locally and systemically catabolic and immunosuppressant. They predispose to specific types of infection, in particular fungi and tuberculosis. In many cases, fungal infections come from a patient's own gut, thru their bloodstream and seeding from the blood into various target tissues like the brain, bone, liver and spleen.

In this case, contamination of the injected solution with fungus was very unlikely-- it was most likely a rare complication of the medication being delivered.

The point about being concerned about UG lab quality assurance is a good one tho. That's why boards like this one provide such an important service to the BB/PL community (those who use AAS)-- they act like a Better Business Bureau for the UG labs: those who stand by their product and use basic QA/QI principles are rewarded, while fly by night operations are financially punished when their reputation gets trashed.

l
 
Back
Top